Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study of GSK2302032A Antigen-Specific Cancer Immunotherapeutic in Patients With Resectable Non-Small Cell Lung Cancer

NCT01159964 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT01159964
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01159964 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study of GSK2302032A Antigen-Specific Cancer Immunotherapeutic in Patients With Resectable Non-Small Cell Lung Cancer
Lead sponsor
GlaxoSmithKline
Phase
Phase 1
Overall status
Terminated
Start date
July 20, 2010
Completion date
September 10, 2014
Enrollment
60 (actual)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer, non-small cell